Alzheimer's disease research, amyloid plaques, tau tangles, and cognitive decline
410 articles
A chromatin-remodeling gene called SMARCAD1 controls tau levels — and switching it off could be a new therapeutic target for Alzheimer's.
A newly identified proteasome activator, PA200, clears toxic alpha-synuclein aggregates and maintains function even when standard protein-disposal systems fail.
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
A JAMA Insights review breaks down how hearing aids work, their limits, and whether OTC devices stack up against prescription options.
A landmark review reframes astrocytes as multilayered processing units that regulate synapses, circuits, and brain function at multiple spatial scales.
Researchers respond to critiques of their trial showing positive airway pressure therapy may improve cognitive outcomes in Parkinson's disease.
New mouse study reveals why women face higher Alzheimer's risk — local brain estrogen deficiency triggers age-specific memory loss and ECM remodeling.
Microglia package healthy mitochondria into vesicles and deliver them to astrocytes, sharply reducing cognitive decline in tau-pathology mice.
New compounds targeting the cPLA2 enzyme may reduce Alzheimer's-linked brain inflammation, especially in high-risk APOE4 gene carriers.
Declining Menin in the hypothalamus drives inflammation and aging. Restoring it reversed decline; D-serine amino acid improved cognition in mice.
A completed RCT tests whether 6 months of moderate aerobic exercise protects memory and brain structure in older adults at genetic risk for Alzheimer's.
A 3-month fish hydrolysate supplement significantly improved episodic memory in healthy seniors showing accelerated cognitive decline, with reduced inflammation markers.
